Phaseline

Companies › Resverlogix

Resverlogix: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Apabetalone (RVX000222)
Bromodomain and extra-terminal motif (BET) inhibitor
BRD2, BRD4, BRDT, BRD3Phase 2Post-Acute COVID-19 Syndrome–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06590324Apabetalone (RVX000222)Phase 2Post-Acute COVID-19 SyndromeInfectious diseaseDec 2025

Targets

BRD2 (1) BRD4 (1) BRDT (1) BRD3 (1)

Companies with the same targets

Novartis Chia Tai Tianqing Pharmaceutical Group Bristol-Myers Squibb

Companies built like this

Vasomune Therapeutics Altesa Biosciences Eagle Pharmaceuticals Code Pharma Peptilogics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.